CUE Quote, Financials, Valuation and Earnings

Nanoviricides has a net margin of -2911.4% compared to Cue Biopharma's net margin of --. Cue Biopharma's return on equity of -200.7% beat Nanoviricides's return on equity of --.

Cue Biopharma has a consensus price target of $4.00, signalling upside risk potential of 577.97%. On the other hand Nanoviricides has an analysts' consensus of -- which suggests that it could grow by 348.28%. Given that Cue Biopharma has higher upside potential than Nanoviricides, analysts believe Cue Biopharma is more attractive than Nanoviricides.

Cue Biopharma has a beta of 1.414, which suggesting that the stock is 41.376% more volatile than S&P 500. In comparison Nanoviricides has a beta of 0.913, suggesting its less volatile than the S&P 500 by 8.749%.

Cue Biopharma has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Nanoviricides offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Cue Biopharma pays -- of its earnings as a dividend. Nanoviricides pays out -- of its earnings as a dividend.

Cue Biopharma quarterly revenues are $421K, which are larger than Nanoviricides quarterly revenues of --. Cue Biopharma's net income of -$12.3M is lower than Nanoviricides's net income of -$2.2M. Notably, Cue Biopharma's price-to-earnings ratio is -- while Nanoviricides's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Cue Biopharma is 4.62x versus -- for Nanoviricides. Usually stocks with elevated PS ratios are considered overvalued.

Oragenics has a net margin of -2911.4% compared to Cue Biopharma's net margin of --. Cue Biopharma's return on equity of -200.7% beat Oragenics's return on equity of --.

Cue Biopharma has a consensus price target of $4.00, signalling upside risk potential of 577.97%. On the other hand Oragenics has an analysts' consensus of $1.00 which suggests that it could grow by 589.72%. Given that Oragenics has higher upside potential than Cue Biopharma, analysts believe Oragenics is more attractive than Cue Biopharma.

Cue Biopharma has a beta of 1.414, which suggesting that the stock is 41.376% more volatile than S&P 500. In comparison Oragenics has a beta of 0.938, suggesting its less volatile than the S&P 500 by 6.243%.

Cue Biopharma has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Oragenics offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Cue Biopharma pays -- of its earnings as a dividend. Oragenics pays out -- of its earnings as a dividend.

Cue Biopharma quarterly revenues are $421K, which are larger than Oragenics quarterly revenues of --. Cue Biopharma's net income of -$12.3M is lower than Oragenics's net income of -$2.2M. Notably, Cue Biopharma's price-to-earnings ratio is -- while Oragenics's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Cue Biopharma is 4.62x versus 1.39x for Oragenics. Usually stocks with elevated PS ratios are considered overvalued.

TG Therapeutics has a net margin of -2911.4% compared to Cue Biopharma's net margin of 4.19%. Cue Biopharma's return on equity of -200.7% beat TG Therapeutics's return on equity of 19.78%.

Cue Biopharma has a consensus price target of $4.00, signalling upside risk potential of 577.97%. On the other hand TG Therapeutics has an analysts' consensus of $41.20 which suggests that it could grow by 15.63%. Given that Cue Biopharma has higher upside potential than TG Therapeutics, analysts believe Cue Biopharma is more attractive than TG Therapeutics.

Cue Biopharma has a beta of 1.414, which suggesting that the stock is 41.376% more volatile than S&P 500. In comparison TG Therapeutics has a beta of 1.937, suggesting its more volatile than the S&P 500 by 93.749%.

Cue Biopharma has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. TG Therapeutics offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Cue Biopharma pays -- of its earnings as a dividend. TG Therapeutics pays out -- of its earnings as a dividend.

Cue Biopharma quarterly revenues are $421K, which are smaller than TG Therapeutics quarterly revenues of $120.9M. Cue Biopharma's net income of -$12.3M is lower than TG Therapeutics's net income of $5.1M. Notably, Cue Biopharma's price-to-earnings ratio is -- while TG Therapeutics's PE ratio is 148.46x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Cue Biopharma is 4.62x versus 14.83x for TG Therapeutics. Usually stocks with elevated PS ratios are considered overvalued.

Theriva Biologics has a net margin of -2911.4% compared to Cue Biopharma's net margin of --. Cue Biopharma's return on equity of -200.7% beat Theriva Biologics's return on equity of --.

Cue Biopharma has a consensus price target of $4.00, signalling upside risk potential of 577.97%. On the other hand Theriva Biologics has an analysts' consensus of $7.00 which suggests that it could grow by 1398.61%. Given that Theriva Biologics has higher upside potential than Cue Biopharma, analysts believe Theriva Biologics is more attractive than Cue Biopharma.

Cue Biopharma has a beta of 1.414, which suggesting that the stock is 41.376% more volatile than S&P 500. In comparison Theriva Biologics has a beta of 0.848, suggesting its less volatile than the S&P 500 by 15.165%.

Cue Biopharma has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Theriva Biologics offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Cue Biopharma pays -- of its earnings as a dividend. Theriva Biologics pays out -- of its earnings as a dividend.

Cue Biopharma quarterly revenues are $421K, which are larger than Theriva Biologics quarterly revenues of --. Cue Biopharma's net income of -$12.3M is lower than Theriva Biologics's net income of -$4.3M. Notably, Cue Biopharma's price-to-earnings ratio is -- while Theriva Biologics's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Cue Biopharma is 4.62x versus 0.33x for Theriva Biologics. Usually stocks with elevated PS ratios are considered overvalued.